Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer

Erratum to: Clin Transl Oncol DOI 10.1007/s12094-014-1243-1

In the published original article, Table 4, column “Frequency” contains some wrong terms.

The correct table is given here.

Table 4.

Studies with gemcitabine and fluoropyrimidines in refractory mCRC

Study	Chemotherapy	Dose mg/m2/d	Frequency	N	RR (%)	Disease control (%)	mPFS	mOS	Neutrop. G3/4 (%)
Fillos [17]	Gemcitabine	750	Day 1 every 7 days × 6	26	3.8	34.8	2.7	11.3	45
	5-FU	450	Day 1 every 7 days × 6
Pachon [19]	Gemcitabine	800–1,250	Day 1, 15 every 21	18	0	70	3.7	9.9	0
	5-FU (IC)	200	Every 21 days
Bitossi [13]	Gemcitabine	1,000	Day 1, 8, 15 every 28	37	10.8	61.8	4.2	8.9	8
	5-FU (IC)	200	Every 28 days
Madaje Wicz [20]	Gemcitabine	900	Day 1 every 7 days × 6	21	38	NR	NR	NR	11
	5-FU	450	Day 1 every 7 days × 6
Schilsky [15]	Gemcitabine	1,000	Day 1, 8, 15 every 28	21	9.6	14.4	NR	NR	7.5
	Capecitabine	1,660	21 days every 28
Fernandez [21]	Gemcitabine	900	Day 1 every 14	21	NR	NR	4	9	NR
	Capecitabine	2,500	7 days every 14
Qiu [18]	Gemcitabine	1,000	Day 1, 8 every 21	12	0	36.4	2.27	5.57	17
	Capecitabine	2,000	14 days every 21
Current study	Gemcitabine	1,000	Day 1 every 14	119	7	45	2.87	6.53	0
	Capecitabine	2,000	7 days every 14

d day, RR response rate, mPFS median progression-free survival, mOS median overall survival, Neutrop neutropenia